Evidence map›Paper›PMID 30122201›Full record

Trial reportClinical lymphoma, myeloma & leukemia2018

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Victor Yazbeck, Danielle Shafer, Edward B Perkins, Domenico Coppola, Lubomir Sokol, Kristy L Richards, Thomas Shea, Jia Ruan, Samir Parekh, Roger Strair and 17 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical lymphoma, myeloma & leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Role of CD36 in cancer progression, stemness, and targeting.Frontiers in cell and developmental biology · 2022
    Review
  4. Programmed cell death, redox imbalance, and cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2021
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. The role of ubiquitination in tumorigenesis and targeted drug discovery.Signal transduction and targeted therapy · 2020
    Review
  11. Article
  12. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.International journal of molecular sciences · 2019
    Review
  13. Review
  14. Article
  15. Article
  16. Bortezomib for the treatment of non-Hodgkin's lymphoma.Expert opinion on pharmacotherapy · 2014
    Review
  17. Article
  18. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Cancer control : journal of the Moffitt Cancer Center · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 1 country.

Victor YazbeckMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Danielle ShaferMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Edward B PerkinsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
Domenico CoppolaDepartment of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL.
Lubomir SokolDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
Kristy L RichardsLineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Thomas SheaLineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Jia RuanDepartment of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Samir ParekhDepartment of Oncology, Montefiore Medical Center, Bronx, NY.
Roger StrairCancer Institute of New Jersey, New Brunswick, NJ.
Christopher FlowersWinship Cancer Institute of Emory University, Atlanta, GA.
David MorganVanderbilt-Ingram Cancer Center, Nashville, TN.
Maciej KmieciakMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Prithviraj BoseMassey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
Amy KimballDepartment of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.
Ashraf Z BadrosDepartment of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD.
Rachid BazDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
Hui-Yi LinDepartment of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL.
Xiuhua ZhaoDepartment of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL.
Richard R ReichDepartment of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, FL.
Mary Beth TombesMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Ellen ShraderMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Heidi SankalaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA.
John D RobertsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
Daniel SullivanDepartment of Blood and Marrow Transplantation and Cellular Immunology, H. Lee Moffitt Cancer Center, Tampa, FL.
Steven GrantMassey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA; Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA; Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA.
Beata HolkovaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA. Electronic address: beata.holkova@vcuhealth.org.
Virginia Commonwealth University · USMoffitt Cancer Center · USUniversity of Maryland, Baltimore · USUniversity of North Carolina at Chapel Hill · USCancer Institute of Florida · USCornell University · USEmory University · USMontefiore Medical Center · USVanderbilt University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Targeting AML with PI3K/AKT inhibitors and BH3-mimeticsR01CA167708 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2013 to 2017
$1.6M
Targeting Multiple Myeloma with Smac-mimetics and HDAC InhibitorsR01CA205607 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2016 to 2020
$1.6M
Wee1 and HDAC inhibition in relapsed/refractory AMLUH2TR001373 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2015 to 2017
$1.6M
NCATS NIH HHS UH2 TR001373NCI NIH HHS HHSN261201100100CNCI NIH HHS P30 CA016059NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA167708NCI NIH HHS R01 CA205607
6 · The paper itself

Abstract

backgroundThe proteasome inhibitor bortezomib has demonstrated marked preclinical activity when combined with the histone deacetylase inhibitor vorinostat in leukemia, multiple myeloma, and mantle cell lymphoma (MCL) cells. The present study evaluated the efficacy and safety of the combination in patients with relapsed or refractory MCL and diffuse large B-cell lymphoma (DLBCL). PATIENTS AND

methodsThe present multicenter, nonrandomized phase II trial used a Simon 2-stage design with 3 cohorts: cohort A, MCL with no previous bortezomib (including untreated MCL); cohort B, MCL with previous bortezomib; and cohort C, relapsed or refractory DLBCL with no previous bortezomib. Vorinostat (400 mg) was administered orally on days 1 to 5 and 8 to 12 before bortezomib (1.3 mg/m

resultsFor the 65 treated patients (22 in cohort A, 4 in cohort B, and 39 in cohort C), the overall response rate was 31.8%, 0%, and 7.7%, respectively. The median progression-free survival was 7.6 months for cohort A and 1.8 months for cohort C. In cohort A, 7 patients had a partial response (PRs), 5 had stable disease (SD), 7 had progressive disease (PD), 1 was not assessed, and 2 were not evaluable. In cohort B, 2 had SD and 2 had PD. In cohort C, 3 had a PR, 8 had SD, 23 had PD, and 5 were not assessed. Baseline NF-κB activation, measured as nuclear RelA by immunohistochemistry, did not correlate with clinical response.

conclusionThe combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL.

Indexed as

Salvage TherapyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisBortezomibVorinostatClinical trialDLBCLHistone deacetylase inhibitorMCLProteasome inhibitors

Identifiers

PMID30122201
PMCPMC11673799
OpenAlexW2805632139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.